Ken Griffin Zai Lab LTD Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$15.95 - $26.8 $126,005 - $211,720	7,900 Added 35.11%	30,400 $487,000
Q4 2023 Feb 14, 2024	BUY	$22.97 - $30.58 $98,771 - $131,494	4,300 Added 23.63%	22,500 $614,000
Q3 2023 Nov 14, 2023	BUY	$22.72 - $31.49 $102,240 - $141,705	4,500 Added 32.85%	18,200 $442,000
Q2 2023 Aug 14, 2023	BUY	$25.3 - $39.67 $129,030 - $202,317	5,100 Added 59.3%	13,700 $379,000
Q1 2023 May 15, 2023	BUY	$30.21 - $48.1 $15,105 - $24,050	500 Added 6.17%	8,600 $286,000

Q4 2022 Feb 14, 2023	SELL	$22.28 - $38.71 $20,052 - $34,839	-900 Reduced 10.0%	8,100 $248,000
Q3 2022 Nov 14, 2022	BUY	$34.2 - $51.69 $20,520 - $31,014	600 Added 7.14%	9,000 $308,000

124

39.9M

41.2K

190K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $1.7B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.